ZLAB

Zai Lab Ltd

Nasdaq · Pharmaceutical Preparations · Inc. E9 · CIK 0001704292

$16.48 -0.84% $1.9B

Insider Selling Cluster (2 insiders)High Impact Filing (7/10)3 New Institutional Positions

Vol

Market Cap$1.9B

Cap SizeSmall Cap

Analyst ConsensusStrong Buy (79%)

Inst. Holders5 funds

Inst. Value$39.5M

Inst. Activity3 buys / 2 sells

Insider Activity0B / 15S

Insider Net $-$4.3M

SEC Reports13

Exchange Nasdaq·Sector Pharmaceutical Preparations·Inc. E9·CIK 0001704292·Prev Close $16.62

Recent Activity

Jun 5, 2026 short_volume

Short Volume: ZLAB — 83.0% short (0.4M / 0.5M)

Short: 435,188 | Exempt: 0 | TRF Vol: 524,159 | Short Ratio: 83.0% | Off-exchange volume (dark pool

May 27, 2026 Insider

Du Ying sold 33,993 shares

Chairperson & CEO @ $0.00 ($0.00)

May 26, 2026 Insider

Du Ying sold 19,857 shares

Chairperson & CEO @ $0.00 ($0.00)

May 21, 2026 SEC

Zai Lab's President and COO Josh Smiley is departing effective immediately, with his last day on May 22, 2026. Responsib

8-K — Impact 4/10

May 21, 2026 SEC

Two Zai Lab insiders (CEO and CLO) sold a combined $1.02M in open-market sales, less than 0.05% of market cap. These sal

CLUSTER — Impact 3/10

May 19, 2026 SEC

CEO Du Ying sold $3.3M worth of ZLAB shares over a 5-day window, primarily through same-day option exercises and open-ma

CLUSTER — Impact 6/10

May 19, 2026 Insider

Du Ying sold 261,092 shares

Chairperson & CEO @ $0.00 ($0.00)

Inst.

FMR LLC — TRIM

1,440,406 shares ($25.4M)

Price Targets

$33.78 +102.9% upside Strong Buy

Current $16.65 Low $21.60 Median $32.24 High $52.00 12 analysts

$21.60 $52.00

Analyst Ratings

Buy79% buy · 14 analysts

2Strong Buy

9Buy

3Hold

0Sell

0Strong Sell

Recent Analyst Actions

Date	Firm	Action	Rating
May 8, 2026	Citigroup	MAINTAIN	Buy → Buy
Mar 18, 2026	JP Morgan	MAINTAIN	Overweight → Overweight
Feb 27, 2026	Cantor Fitzgerald	MAINTAIN	Overweight → Overweight
Feb 5, 2026	JP Morgan	MAINTAIN	Overweight → Overweight
Jan 7, 2026	UBS	INITIATE	Buy

Earnings Estimates

Period	EPS Est.	Range	Growth	#
Current Q	$-0.67 ▼ -37.0%	$-0.99 — $-0.52	-80% YoY	6
Next Q	$-0.53 ▼ -12.4%	$-0.61 — $-0.40	-60% YoY	6
Current FY	$-2.16 ▼ -12.6%	$-2.64 — $-1.77	-35% YoY	11
Next FY	$-1.75 ▼ -25.1%	$-2.35 — $-1.17	19% YoY	11

Latest Reports

NEUTRAL 8-K 4/10

Zai Lab's President and COO Josh Smiley is departing effective immediately, with his last day on May 22, 2026. Responsib

May 21, 2026

NEUTRAL CLUSTER 3/10

Two Zai Lab insiders (CEO and CLO) sold a combined $1.02M in open-market sales, less than 0.05% of market cap. These sal

May 21, 2026

Top Institutional Holders

Fund	Value	Move
FMR LLC	$25.4M	TRIM
BANK OF AMERICA CORP	$6.9M	DOUBLED
MORGAN STANLEY	$5.1M	DOUBLED
WELLS FARGO & COMPANY/MN	$1.6M	TRIM
TWO SIGMA INVESTMENTS, LP	$520.8K	NEW

Recent Insider Trades

Date	Insider	Type	Value
May 27, 2026	Du Ying	G	$0.00
May 26, 2026	Du Ying	G	$0.00
May 19, 2026	Du Ying	M	$0.00
May 19, 2026	Du Ying	F	$2.2M
May 19, 2026	Du Ying	M	$454.3K

5 institutional holders with $39.5M total value (2,241,543 shares) as of 2025-Q4. Top holders: FMR, BANK, MORGAN. Net buying activity: 3 institutions added/increased vs 2 reduced.

Top Institutional Holders — 2025-Q4

#	Fund	Shares	Value	% of Tracked	Last Move
1	FMR LLC	1,440,406	$25.4M	64.3%	TRIM -69.4%
2	BANK OF AMERICA CORP /DE/	388,769	$6.9M	17.3%	DOUBLED +173.1%
3	MORGAN STANLEY	289,705	$5.1M	12.9%	DOUBLED +141.7%
4	WELLS FARGO & COMPANY/MN	93,140	$1.6M	4.2%	TRIM -46.8%
5	TWO SIGMA INVESTMENTS, LP	29,523	$520.8K	1.3%	NEW

Recent Position Changes

Fund	Action	Prev Shares	Curr Shares	Change %	Value	Quarter
FMR LLC	TRIM	4,701,711	1,440,406	-69.4%	$25.4M	2025-Q4
BANK OF AMERICA CORP /DE/	DOUBLED	142,374	388,769	+173.1%	$6.9M	2025-Q4
MORGAN STANLEY	DOUBLED	119,880	289,705	+141.7%	$5.1M	2025-Q4
WELLS FARGO & COMPANY/MN	TRIM	175,132	93,140	-46.8%	$1.6M	2025-Q4
TWO SIGMA INVESTMENTS, LP	NEW	—	29,523	—	$520.8K	2025-Q4
UBS Group AG	ADD	241,650	306,554	+26.9%	$10.4M	2025-Q3
MORGAN STANLEY	TRIM	289,101	119,880	-58.5%	$4.1M	2025-Q3
RENAISSANCE TECHNOLOGIES LLC	EXIT	232,900	0	-100.0%	$0.00	2025-Q3
MORGAN STANLEY	NEAR_EXIT	2,634,559	289,101	-89.0%	$10.1M	2025-Q2
UBS Group AG	TRIM	393,117	241,650	-38.5%	$8.5M	2025-Q2
RENAISSANCE TECHNOLOGIES LLC	DOUBLED	84,500	232,900	+175.6%	$8.1M	2025-Q2
WELLS FARGO & COMPANY/MN	ADD	138,830	174,480	+25.7%	$6.1M	2025-Q2
BANK OF AMERICA CORP /DE/	TRIM	232,503	149,744	-35.6%	$5.2M	2025-Q2
TWO SIGMA INVESTMENTS, LP	EXIT	55,843	0	-100.0%	$0.00	2025-Q2
CITADEL ADVISORS LLC	ADD	262,152	442,469	+68.8%	$16.0M	2025-Q1
UBS Group AG	TRIM	878,802	393,117	-55.3%	$14.2M	2025-Q1
WELLS FARGO & COMPANY/MN	DOUBLED	40,954	138,830	+239.0%	$5.0M	2025-Q1
RENAISSANCE TECHNOLOGIES LLC	TRIM	187,800	84,500	-55.0%	$3.1M	2025-Q1
TWO SIGMA INVESTMENTS, LP	ADD	29,757	55,843	+87.7%	$2.0M	2025-Q1
MORGAN STANLEY	ADD	1,714,357	3,166,946	+84.7%	$82.9M	2024-Q4
UBS Group AG	DOUBLED	18,258	878,802	+4713.2%	$23.0M	2024-Q4
CITADEL ADVISORS LLC	NEAR_EXIT	1,425,972	262,152	-81.6%	$6.9M	2024-Q4
RENAISSANCE TECHNOLOGIES LLC	DOUBLED	88,300	187,800	+112.7%	$4.9M	2024-Q4
WELLS FARGO & COMPANY/MN	DOUBLED	500	40,954	+8090.8%	$1.1M	2024-Q4
MORGAN STANLEY	DOUBLED	543,814	1,714,357	+215.2%	$41.4M	2024-Q3

6 unique insiders with 15 transactions. Net insider value: -$4.3M ($0.00 bought, $4.3M sold).

Insider Transactions

Date	Insider	Title	Type	Shares	Price	Value
May 27, 2026	Du Ying	Chairperson & CEO	G	33,993	$0.00	$0.00
May 26, 2026	Du Ying	Chairperson & CEO	G	19,857	$0.00	$0.00
May 19, 2026	Du Ying	Chairperson & CEO	M	261,092	$0.00	$0.00
May 19, 2026	Du Ying	Chairperson & CEO	F	117,435	$18.75	$2.2M
May 19, 2026	Du Ying	Chairperson & CEO	M	261,092	$1.74	$454.3K
May 18, 2026	Du Ying	Chairperson & CEO	M	50,000	$0.00	$0.00
May 18, 2026	Du Ying	Chairperson & CEO	SELL	50,000	$19.00	$949.8K
May 18, 2026	Du Ying	Chairperson & CEO	M	50,000	$1.74	$87.0K
May 15, 2026	Du Ying	Chairperson & CEO	M	50,000	$0.00	$0.00
May 15, 2026	Du Ying	Chairperson & CEO	SELL	50,000	$20.74	$1.0M
May 15, 2026	Du Ying	Chairperson & CEO	M	50,000	$1.74	$87.0K
May 14, 2026	Du Ying	Chairperson & CEO	M	50,000	$1.74	$87.0K
May 14, 2026	Du Ying	Chairperson & CEO	SELL	50,000	$20.09	$1.0M
May 14, 2026	Du Ying	Chairperson & CEO	M	50,000	$0.00	$0.00
May 14, 2026	Edmondson Frazor Titus III	Chief Legal Officer	SELL	3,517	$20.19	$71.0K
May 13, 2026	Du Ying	Chairperson & CEO	M	50,000	$1.74	$87.0K
May 13, 2026	Du Ying	Chairperson & CEO	SELL	16,231	$19.44	$315.6K
May 13, 2026	Du Ying	Chairperson & CEO	M	50,000	$0.00	$0.00
May 11, 2026	Wang Yizhe	Operating Partner	A	59,288	$0.00	$0.00
May 11, 2026	Wang Yizhe	Operating Partner	A	136,819	$0.00	$0.00
Apr 6, 2026	Amado Rafael	See Remarks	SELL	2,739	$20.45	$56.0K
Apr 6, 2026	Du Ying	Chairperson & CEO	SELL	2,653	$20.45	$54.2K
Apr 6, 2026	Chen Yajing	Chief Financial Officer	SELL	853	$20.45	$17.4K
Apr 6, 2026	Edmondson Frazor Titus III	Chief Legal Officer	SELL	1,224	$20.45	$25.0K
Apr 6, 2026	Smiley Joshua L	See Remarks	SELL	3,017	$20.45	$61.7K
Apr 2, 2026	Du Ying	Chairperson & CEO	M	6,750	$0.00	$0.00
Apr 2, 2026	Du Ying	Chairperson & CEO	SELL	5,576	$20.39	$113.7K
Apr 2, 2026	Du Ying	Chairperson & CEO	M	6,750	$0.00	$0.00
Apr 2, 2026	Chen Yajing	Chief Financial Officer	M	2,500	$0.00	$0.00
Apr 2, 2026	Amado Rafael	See Remarks	M	5,391	$0.00	$0.00
Apr 2, 2026	Chen Yajing	Chief Financial Officer	SELL	5,199	$20.39	$106.0K
Apr 2, 2026	Chen Yajing	Chief Financial Officer	M	2,500	$0.00	$0.00
Apr 2, 2026	Amado Rafael	See Remarks	M	5,391	$0.00	$0.00
Apr 2, 2026	Amado Rafael	See Remarks	SELL	9,910	$20.39	$202.1K
Apr 2, 2026	Smiley Joshua L	See Remarks	M	7,145	$0.00	$0.00
Apr 2, 2026	Smiley Joshua L	See Remarks	SELL	9,614	$20.39	$196.0K
Apr 2, 2026	Smiley Joshua L	See Remarks	M	7,145	$0.00	$0.00
Apr 2, 2026	Edmondson Frazor Titus III	Chief Legal Officer	SELL	4,194	$20.39	$85.5K
Apr 2, 2026	Edmondson Frazor Titus III	Chief Legal Officer	M	5,031	$0.00	$0.00
Apr 2, 2026	Edmondson Frazor Titus III	Chief Legal Officer	M	5,031	$0.00	$0.00
Apr 1, 2026	Edmondson Frazor Titus III	Chief Legal Officer	M	2,671	$0.00	$0.00
Apr 1, 2026	Du Ying	Chairperson & CEO	M	10,800	$0.00	$0.00
Apr 1, 2026	Du Ying	Chairperson & CEO	M	10,800	$0.00	$0.00
Apr 1, 2026	Chen Yajing	Chief Financial Officer	M	1,500	$0.00	$0.00
Apr 1, 2026	Chen Yajing	Chief Financial Officer	M	1,500	$0.00	$0.00
Apr 1, 2026	Amado Rafael	See Remarks	M	19,523	$0.00	$0.00
Apr 1, 2026	Amado Rafael	See Remarks	M	19,523	$0.00	$0.00
Apr 1, 2026	Smiley Joshua L	See Remarks	M	32,062	$0.00	$0.00
Apr 1, 2026	Edmondson Frazor Titus III	Chief Legal Officer	M	2,671	$0.00	$0.00
Apr 1, 2026	Smiley Joshua L	See Remarks	M	32,062	$0.00	$0.00

13 SEC filing reports analyzed. Sentiment: 1 bullish, 4 bearish, 0 mixed, 8 neutral. Avg impact: 4.4/10.

NEUTRAL 8-K 4/10

Zai Lab's President and COO Josh Smiley is departing effective immediately, with his last day on May

May 21, 2026

NEUTRAL CLUSTER 3/10

Two Zai Lab insiders (CEO and CLO) sold a combined $1.02M in open-market sales, less than 0.05% of m

May 21, 2026

BEARISH CLUSTER 6/10

CEO Du Ying sold $3.3M worth of ZLAB shares over a 5-day window, primarily through same-day option e

May 19, 2026

BEARISH 8-K 6/10

Zai Lab reported Q1 2026 total revenue of $99.6M, down 6% YoY from $106.5M, and product revenue of $

May 7, 2026

NEUTRAL DEFA14A 2/10

Zai Lab Ltd filed a DEFA14A (additional definitive proxy soliciting materials) on April 28, 2026. Th

Apr 28, 2026

NEUTRAL 144 3/10

Rafael Amado, an officer of Zai Lab, filed a Form 144 to notify intent to sell 2,739 American Deposi

Apr 6, 2026

NEUTRAL 144 3/10

Yajing Chen, an officer of Zai Lab Ltd, filed a Form 144 to report the proposed sale of 853 American

Apr 6, 2026

BEARISH CLUSTER 5/10

A cluster of insider transactions at Zai Lab Ltd (ZLAB) over the past week shows one director buying

Mar 19, 2026

NEUTRAL CLUSTER 4/10

Zai Lab CEO Du Ying exercised stock options and sold a small number of shares in the open market, wh

Mar 16, 2026

NEUTRAL CLUSTER 3/10

Zai Lab CEO Du Ying exercised stock options to acquire shares and sold a portion of her holdings in

Mar 12, 2026

BEARISH CLUSTER 7/10

Zai Lab's CEO Du Ying exercised and sold shares across multiple transactions, generating $1.92M from

Mar 10, 2026

NEUTRAL CLUSTER 3/10

A recent insider trading cluster at Zai Lab includes open-market sales by the Chief Legal Officer an

Mar 6, 2026

BULLISH 8-K 8/10

Zai Lab reported strong financial results for Q4 and full-year 2025, with total revenue growing 17%

Feb 26, 2026

∅

No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.

Current analyst consensus: Buy (79% buy). Based on 14 analysts: 2 strong buy, 9 buy, 3 hold, 0 sell, 0 strong sell.

Analyst Price Targets

$33.78 mean target +102.9% upside Strong Buy (3.00)

$21.60 Low $52.00 High

Metric	Value
Current Price	$16.65
Target Low	$21.60
Target Mean	$33.78
Target Median	$32.24
Target High	$52.00
# Analysts	12
Recommendation	Strong Buy (3.00)

Earnings Estimates & Revisions

Period	EPS Avg	EPS Low	EPS High	EPS Growth	30d Rev.	Up/Down	Rev. Avg	Rev. Growth	Analysts
Current Q 2026-06-30	$-0.67	$-0.99	$-0.52	-80.4%	-37.0%	0↑ 4↓	$0.1B	-5.5%	6
Next Q 2026-09-30	$-0.53	$-0.61	$-0.40	-59.7%	-12.4%	1↑ 3↓	$0.1B	-4.6%	6
Current FY 2026-12-31	$-2.16	$-2.64	$-1.77	-35.2%	-12.6%	1↑ 8↓	$0.5B	-2.1%	11
Next FY 2027-12-31	$-1.75	$-2.35	$-1.17	19.3%	-25.1%	0↑ 9↓	$0.6B	32.6%	11

Current Quarter EPS Revision History

Timepoint	EPS Estimate	Change
Current	$-0.668
7d ago	$-0.604	-0.064
30d ago	$-0.487	-0.180
60d ago	$-0.470	-0.198
90d ago	$-0.293	-0.374

4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.

Individual Analyst Actions

Date	Analyst Firm	Action	Previous Rating	New Rating
May 8, 2026	Citigroup	MAINTAIN	Buy	Buy
Mar 18, 2026	JP Morgan	MAINTAIN	Overweight	Overweight
Feb 27, 2026	Cantor Fitzgerald	MAINTAIN	Overweight	Overweight
Feb 5, 2026	JP Morgan	MAINTAIN	Overweight	Overweight
Jan 7, 2026	UBS	INITIATE	—	Buy

Monthly Consensus History

Period	Strong Buy	Buy	Hold	Buy %
Jun 1, 2026	2	9	3	79%
May 1, 2026	2	9	3	79%
Apr 1, 2026	2	9	3	79%
Mar 1, 2026	2	9	3	79%
Feb 1, 2026	2	9	3	79%
Jan 1, 2026	2	9	3	79%

Strong BuyBuyHoldSellStrong Sell

∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

Jun 5, 2026

short_volume

Short Volume: ZLAB — 83.0% short (0.4M / 0.5M)

Short: 435,188 | Exempt: 0 | TRF Vol: 524,159 | Short Ratio: 83.0% | Off-exchange volume (dark pool + OTC)

May 18, 2026

short_volume

Short Volume: ZLAB — 56.5% short (0.4M / 0.7M)

Short: 415,103 | Exempt: 0 | TRF Vol: 735,165 | Short Ratio: 56.5% | Off-exchange volume (dark pool + OTC)

May 10, 2026

fda_pdufa

PDUFA: ZLAB — VYVGART in acetylcholine receptor antibody (AChR-Ab) seronegative generalized myasthenia gravis (sn-gMG) — 2026-05-10

FDA target action date 2026-05-10 for ZLAB (Zai Lab Ltd). Drug: VYVGART. Indication: acetylcholine receptor antibody (AChR-Ab) seronegative generalize

Apr 17, 2026

short_interest

FTD: ZLAB — 182,717 shares ($4.3M) failed to deliver

Settlement: 20260417, Price: $23.50, FTD Value: $4,293,849.5, ZAI LAB LTD

Apr 16, 2026

short_interest

FTD: ZLAB — 123,176 shares ($2.9M) failed to deliver

Settlement: 20260416, Price: $23.25, FTD Value: $2,863,842, ZAI LAB LTD

Apr 15, 2026

short_interest

FTD: ZLAB — 74,265 shares ($1.6M) failed to deliver

Settlement: 20260415, Price: $21.96, FTD Value: $1,630,859.4, ZAI LAB LTD

Apr 15, 2026

short_volume

Short Volume: ZLAB — 55.4% short (0.3M / 0.6M)

Short: 306,942 | Exempt: 6,320 | TRF Vol: 553,746 | Short Ratio: 55.4% | Off-exchange volume (dark pool + OTC)

Apr 10, 2026

short_interest

FTD: ZLAB — 92,188 shares ($1.9M) failed to deliver

Settlement: 20260410, Price: $20.74, FTD Value: $1,911,979.12, ZAI LAB LTD

Apr 8, 2026

short_interest

FTD: ZLAB — 52,750 shares ($1.1M) failed to deliver

Settlement: 20260408, Price: $21.00, FTD Value: $1,107,750, ZAI LAB LTD

Apr 7, 2026

short_interest

FTD: ZLAB — 54,465 shares ($1.1M) failed to deliver

Settlement: 20260407, Price: $20.50, FTD Value: $1,116,532.5, ZAI LAB LTD

Mar 27, 2026

short_interest

FTD: ZLAB — 60,611 shares ($1.1M) failed to deliver

Settlement: 20260327, Price: $17.51, FTD Value: $1,061,298.61, ZAI LAB LTD

Mar 25, 2026

short_interest

FTD: ZLAB — 110,350 shares ($1.9M) failed to deliver

Settlement: 20260325, Price: $17.47, FTD Value: $1,927,814.5, ZAI LAB LTD

Mar 23, 2026

short_interest

FTD: ZLAB — 43,901 shares ($0.8M) failed to deliver

Settlement: 20260323, Price: $18.09, FTD Value: $794,169.09, ZAI LAB LTD

Mar 20, 2026

short_interest

FTD: ZLAB — 168,321 shares ($3.1M) failed to deliver

Settlement: 20260320, Price: $18.61, FTD Value: $3,132,453.81, ZAI LAB LTD

Mar 18, 2026

short_interest

FTD: ZLAB — 42,103 shares ($0.8M) failed to deliver

Settlement: 20260318, Price: $19.02, FTD Value: $800,799.06, ZAI LAB LTD